What We Do > Specialties > Respiratory > Respiratory Medications
TOBRAMYCIN
At Foundation Care, we are working to make life easier for those with Cystic Fibrosis. If you
allow us, we can take away the hassle of preparing your Tobramycin prescription for use in
the eFlow® SCF . Our pharmacists will do the work for you, preparing the medication in
easy to use unit dose neb vials.
Foundation Care will customize your patient's medication by preparing Tobramycin for use
in the eFlow® SCF to your specification. As the physician, you decide the concentration
and volume of each dose to be prepared for your patients.
Dosage Forms Commonly Used in the Treatment of Cystic Fibrosis
- 170mg dose BID for inhalation with an eFlow® SCF nebulizer
- 150mg dose BID for inhalation with an eFlow® SCF nebulizer. For an eFlow® SCF Tobramycin study click here.
Patients receiving chronic antibiotic therapy of Tobramycin may qualify to receive FREE
SourceCF Multivitamins (Softgels, Chewables, and Pediatric Drops) with each prescription.
Patients receiving chronic antibiotic therapy of Tobramycin and Hypertonic Saline from
Foundation Care may qualify for our FREE Hypertonic Saline program.
Unit dose Tobramycin should be stored under refrigeration and is good for up to 60 days.
Each dose should be inspected prior to administration.
If you have any questions about your medication, please contact a patient service
representative at (314) 291-1122 or toll free (877) 291-1122.
Disclaimer: Foundation Care is a licensed compounding pharmacy that only engages in compounding in a response to a doctor's
prescription. Prescriptions compounded are sold or offered as an alternative to patients whose medical needs are not met by other
therapies. The safety or effectiveness of compounded prescription products have not been reviewed by the U.S. FDA as to either their
safety or efficacy. Foundation Care conducts its compounding activities in compliance with the FDA's Compliance Policy Guide, Section
460.200 and USP 797 Guidelines.
Chiron Disclaimer
The eFlow® SCF has not undergone human clinical studies to determine its safety or efficacy and has not been approved by the FDA for
use with tobramycin in the treatment of Pseudomonas aeruginosa in patients with Cystic Fibrosis. Compounded prescriptions are not
evaluated by the FDA for safety of efficacy.